Cascadian Therapeutics Inc.
(NASDAQ : CASC)

( )
CASC After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Yes, 3x ETFs are Awesome!
Like TNA, UGAZ, UWTI, NUGT? We do too...Join Up!
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
GILDGilead Sciences, Inc.
0.55%73.740.9%$598.99m
CELGCelgene Corporation
-0.84%129.191.1%$425.21m
AMGNAmgen Inc.
-0.63%169.001.1%$397.19m
BIIBBiogen Inc.
-1.42%282.641.2%$346.45m
REGNRegeneron Pharmaceuticals, Inc.
-0.31%477.152.7%$319.17m
VRTXVertex Pharmaceuticals Incorporated
-1.43%153.251.9%$227.49m
ALXNAlexion Pharmaceuticals, Inc.
-1.83%135.671.9%$211.59m
ILMNIllumina, Inc.
-0.59%193.623.5%$208.34m
KITEKite Pharma, Inc.
1.63%138.1716.1%$135.10m
INCYIncyte Corporation
-0.17%123.652.6%$130.04m
CLVSClovis Oncology, Inc.
-0.68%71.6118.0%$125.25m
TSROTESARO, Inc.
-0.18%120.4014.7%$124.85m
AAgilent Technologies, Inc.
-0.30%62.771.5%$122.45m
BMRNBioMarin Pharmaceutical Inc.
-0.07%81.404.4%$105.16m
SRPTSarepta Therapeutics, Inc.
-2.38%36.0719.8%$88.80m

Company Profile

Cascadian Therapeutics, Inc. is a clinical-stage biopharmaceutical company, focuses on the development of therapeutic products for the treatment of cancer. Its lead product candidate ONT-380, is an orally active and selective small-molecule HER2 inhibitor. It also develops preclinical product candidates in oncology using Chk1 kinase inhibitor and protocell technology. The company was founded on September 7, 2007 and is headquartered in Seattle, WA